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Abstract
Background: Prostate cancer (PC) is the most common cancer among men in the western world. 
Genetic lifetime risk assessment could alleviate controversies about prostate specific antigen (PSA) 
testing for early diagnosis.
Aim: To determine how men interpret information about their lifetime risk for PC and how this can 
affect their choice of having a repeated PSA test.
Design & setting: A genetic test was offered for assessment of individual PC lifetime risk in general 
practices in Denmark, with the purpose of promoting appropriate use of PSA testing.
Method: Participants had a genetic lifetime risk assessment for PC diagnosis (either high or normal 
risk). A month after receiving the result, participants answered a questionnaire about their perceived 
risk of getting or dying from PC compared with other men, as well as their intentions for repeated 
PSA testing.
Results: Nearly half (44.7%) of 555 participants who received the genetic risk assessment were not 
aware they had a genetic test. Nevertheless, compared with men with a normal genetic risk, those 
with high genetic risk reported higher perceived risk for PC (mean difference of 0.74 [95% confidence 
interval {CI} = 0.56 to 0.96] on a 5- point scale), higher perceived risk of dying from PC (mean difference 
of 0.48 [95% CI = 0.29 to 0.66] on a 5- point scale), and increased intention for repeated PSA testing 
(mean difference of 0.48 [95% CI = 0.30 to 0.65] on a 4- point scale).
Conclusion: Despite low awareness and/or understanding of the test result, a high genetic risk for 
PC made participants more aware of their risk, and it increased their intention and probability for 
repeated PSA testing.
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How this fits in
Most guidelines advise against population- based screening using the PSA test. Here, a genetic test 
was offered for assessment of individual PC lifetime risk in Danish general practice, with the purpose 
of promoting appropriate use of PSA testing. A month after receiving the result, participants answered 
a questionnaire about their perceived risk of getting or dying from PC, as well as their intentions for 
repeated PSA testing. Despite low awareness and/or understanding of the test result, having a high 
genetic risk for PC made participants more aware of their risk, and it increased their intention and 
probability for repeated PSA testing.
Introduction
PC is the most common cancer among men in Europe, with approximately 190 000 new cases 
and about 80 000 deaths every year.1–4 A commonly used method for early detection of PC is the 
PSA test, although this method has limited accuracy.5,6 This results in failure to detect genuinely 
aggressive disease at an early stage, as well as overdiagnosis and overtreatment of indolent cancers 
that would not give rise to symptoms in the patient’s normal lifespan if left undetected. Therefore, 
most guidelines advise against population- based screening using the PSA test.7,8 Still, the PSA test is 
frequently requested by some men and opportunistically offered by GPs, typically in relation to lower 
urinary tract symptoms (LUTS) or regular health checks.9
Risk stratification has been proposed as a strategy to improve the benefit- to- harm ratio of 
(opportunistic) PSA screening by targeting PSA testing to those men most likely to benefit.10 
Genetic markers are candidates to provide such risk assessment for PC, and advances in genome- 
wide association studies have so far identified around 200 genetic variants associated with higher 
PC lifetime risk, termed single nucleotide polymorphisms (SNPs).11–14 Furthermore, retrospective 
studies comparing non- genetic risk prediction models versus risk prediction models, including 
genetic markers (SNPs), have reported significantly higher specificity for the genetic models.15–17 
From a patient perspective, knowledge of one’s lifetime PC risk could enhance accuracy of perceived 
susceptibility18,19 and aid in shared decision- making about PSA testing.20
To the authors' knowledge, no previous clinical studies have investigated if a genetic PC risk 
assessment can be utilised as a tool for optimising the use of PSA testing in a general practice setting. 
An intervention was previously developed21,22 in which a genetic lifetime risk assessment for PC was 
offered to patients who had a PSA test at their general practice. The aim was to enhance appropriate 
PSA testing by: (a) reducing the number of unnecessary PSA tests (opportunistic screening) in men 
with a normal lifetime risk; and (b) promoting targeted PSA screening of high- risk men (≥30% lifetime 
risk) to ensure early detection. The result of a genetic PC risk assessment could then support decisions 
where both patient and GP had additional information about the future risk of getting a PC diagnosis.
The aim of this study was to explore whether patients were aware of the genetic test, and how 
information about lifetime risk influenced their perceived risk of PC and their intentions to have a 
repeated PSA test in the future.
Method
Study setting and participants
The study was performed in 73 general practices in the Central Region of Denmark. Citizens are 
registered with a specific general practice, which they have to consult for medical advice, and the GP 
acts as gatekeeper for the rest of the healthcare system.
All patients were included from the intervention arm of the ProCaRis project21 from January 2013 
to December 2013. The aim of the ProCaRis project was to identify a group of patients for whom 
PSA testing would have most benefit, by introducing a genetic test for lifetime risk of PC in general 
practice. In brief, all patients who received a PSA test at their general practice within the study period 
were eligible for inclusion, unless they showed one of the following exclusion criteria: aged >80 years; 
elevated PSA level (≥4 µg/l) concurrently or within the previous 2 years; known prostate or bladder 
disease; or a history of PC. As little control as possible was asserted over the entire inclusion process 
to minimise any disturbances to the normal workflow and, consequently, the reasoning behind the 
initial PSA test was not known to the authors; it was left solely to the GP and patient’s discretion. 
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In addition to having a PSA test, eligible patients had an additional 4 ml blood sample drawn for a 
genetic risk assessment.
Based on genotyping of 33 risk loci and/or SNPs (adjusted for age and PC family history), the 
individual lifetime PC risk was calculated for each participant as previously described,21,23 and results 
reported as high, normal, or unknown risk. As the lifetime risk score was adjusted for age in the 
algorithm, no further distinction was made between younger and older participants. A high lifetime 
risk was considered as an absolute lifetime risk of ≥30%, which is nearly three times higher than the 
average lifetime risk of 11% and thus comparable with the Danish recommendation to only offer PSA 
testing in men aged >45 years, with a family history of PC (two close relatives), and to those with 
a life expectancy of >10–15 years.8,24–26 A lifetime risk <30% was considered 'normal'. In the rare 
cases, where the patient’s family disposition was unknown but the total risk assessment, in theory, 
would change from ‘normal’ to ‘high’ in the case of a known positive family history, the total risk 
assessment result was reported as ‘unknown’. Accordingly, after determining the risk profile (with a 
mean response time of 21 days after the blood sampling), one of the following messages was sent 
electronically to the GP:
Normal lifetime risk
'The patient belongs to a group of patients at normal lifetime risk of getting a prostate cancer 
diagnosis. It is not considered necessary or beneficial for the patient to have more PSA tests in the 
future, unless the patient develops urinary tract symptoms or one or more of his relatives develops 
prostate cancer.'
high lifetime risk
'The patient belongs to a group with increased risk of developing prostate cancer in the future. If the 
patient develops prostate cancer in the future, in most cases, the cancer will be slow growing. For 
early detection, the patient is encouraged to have a yearly PSA test.'
Unknown lifetime risk
'The risk for developing prostate cancer in the future cannot be estimated due to missing information 
for family history.'
The GP or their staff then informed the patient about the result by telephone, email, letter, or during 
consultation. Before the study, each practice had received written information with recommendations 
about follow- up PSA testing, according to current guidelines and information about the benefits and 
shortcomings of genetic risk assessment as a tool to support decision making about testing for PC. 
The researchers provided additional online information about PC screening, use of PSA tests, and 
genetic risk assessment for PC, as well as a project telephone hotline.21,27
Measures
PSA test results were collected from the regional clinical laboratory information system (LABKA) and 
included the PSA level at the time of inclusion and any PSA test(s) performed during the following 2 
years after the patient’s initial PSA test.
Questionnaires were sent to participants about 1 month after the genetic test result was available 
to the GP (and thus, approximately 2 months after initial inclusion); a reminder was sent 2 weeks later 
if the questionnaire had not been returned. The questionnaires contained questions about patients’ 
awareness of their lifetime risk of PC, their perceived risk of developing PC, of their overall health, and 
of their intentions to have a repeat PSA test in the future (Table 1).
The genetic lifetime risk (normal, high, or unknown) results were collected directly from the 
laboratory at the Department of Molecular Medicine, Aarhus University Hospital, Denmark, where all 
genetic analyses were performed.
Statistical analysis
All statistical analyses were performed in R28 (version 3.5.1) using R studio (version 1.1.383). Fisher's 
exact test was used to test differences in distributions, while differences in means or medians were 
tested by Student t- test or Wilcoxon rank sum test, respectively. CIs were calculated from a two- sided 
Student t- test.
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Univariate and multivariate Cox regression analyses were performed using the survival package,29 
and the endpoint was a repeat PSA test within 2 years. Patients who did not have a repeat PSA test 
within that timeframe were censored at 730 days (that is, 2 years). P values <0.05 and/or differences 
outside 95% CIs were considered significant.
To explore which factors were associated with patients’ decisions to have a repeat PSA test, a 
multivariate Cox regression model was created using a repeat PSA test within 2 years as endpoint. 
Consequently, the study used genetic risk, perceived risk for PC diagnosis, perceived risk for dying of 
Table 1 Summary of patient questionnaire used in this study. The full questionnaire participants 
received is available on request.
Question 
label Text Response
q01 Did you have a PSA test? 1 = yes, 0 = no
q02 Why did you take the PSA test?
q02_1 I have / had urinary problems
q02_2 I got the test, as I still was at the doctor in 
connection with another health problem
q02_3 I got it taken in conjunction with a regular 
health check
q02_4 I got the test because I was worried that 
I have PC
q02_5 I got it taken to be sure that I do not have 
PC
q02_6 I had not even considered getting test 
before my doctor recommended me
q02_7 My family has advised me to take the test
q02_8 My friends / acquaintances have advised 
me to take the test
q02_9 I have friends / acquaintances who have 
had PC and are living with it today
q02_10 I have friends / acquaintances who have 
died of PC
q02_11 I have had PC
q02_12 I have had another type of cancer
q02_13 I have had an elevated PSA level
q02_14 Other reason. Please specify
q03 How were the results of the PSA test? 1 = normal, 2 = increased, 9 = don't know
q04 How do you assess your risk of getting 
PC, compared with other men your age?
1 = much lower, 2 = lower, 3 = the same, 4 = higher, 5 
= much higher
q05 How do you assess your risk of dying from 
PC compared with other men your age?
1 = much lower, 2 = lower, 3 = the same, 4 = higher, 5 
= much higher
q06 Although my PSA level is normal now, I 
am determined to ask my doctor for a 
new PSA test over the next 2 years
1 = totally disagree, 2 = disagree, 3 = agree, 4 = totally 
agree, 9 = don't know
q07 How do you think your health is overall? 1 = bad, 2 = less good, 3 = good, 4 = very good, 5 = 
excellent
q08 Have you had taken a genetic test? 1 = yes, 0 = no
q09 How was the result of your genetic 
testing?
1 = normal, 2 = increased, 9 = don't know
PC = prostate cancer. PSA = prostate specific antigen.
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PC, intention for a repeat PSA test, PSA level at inclusion, and awareness of having had a genetic test 
as possible explanatory variables.
Results
Questionnaire response rate
In total, 810 patients received a genetic test in 73 general practices. Of these, 787 patients (97.2%, 
Figure 1) were eligible and received the questionnaire (Table 1). After removing non- responders (n = 
133, 16.4%), patients with PSA ≥4 µg/l at inclusion (n = 91, 11.2%), patients aged 80 years (n = 1, 0.1%), or 
unknown genetic risk (n = 7, 0.9%), a total of 555 patients (68.5%) were included in the analysis (Table 2).
Patients’ understanding of their test results
Slightly more than half of the responders (n = 306, 55.1%) recalled they had a genetic test performed 
(q08, Table 1 and Figure 2a). The awareness of having had a genetic test was not significantly different 
Genetic test
n = 810 (100%)
Non-eligible
E.g. protected address
n = 23 (2.8%)
Sent survey
n = 787 (97.2%)
Non-responders
n = 133 (16.4%)
PSA at inclusion ≥ 4
n = 91 (11.2%)
Age at inclusion > 80
n = 1 (0.1%)
Included in analysis
n = 555 (68.5%)
Genetic risk unknown
n = 7 (0.9%)
Figure 1 Flow chart of inclusion and exclusion criteria. PSA = prostate specific antigen.
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(Fisher’s test, P = 0.379) for patients with a high versus a normal risk test result (Figure 2a). When the 
patients who were aware they had received a genetic test were asked about the result of their genetic 
test (that is, lifetime genetic risk), patients with a normal genetic lifetime risk correctly reported their 
risk in 98.5% (n = 258/262) of cases, while a significantly smaller fraction (75.0%, n = 33/44) of patients 
with high genetic risk reported correctly (Figure 2b; Δ = 0.23; t- test, P<0.001; 95% CI = 0.10 to 0.37).
For comparison, the patients’ knowledge about their PSA test result at inclusion was also analysed. 
For this analysis only, all responders were incorporated, including also those (n = 87) with a PSA level 
≥4 µg/l at inclusion. Only 51.7% of patients with PSA levels ≥4 µg/l correctly reported their PSA levels 
as elevated (Figure 2c). In contrast, participants with normal PSA levels (<4 µg/l) correctly reported 
their PSA levels as normal in 85.6% of the cases (Figure 2c; change (Δ) = 0.34; t- test, P<0.001; 95% 
CI = 0.23 to 0.45).
The patients’ perceived risk of PC correlated with actual genetic risk
No significant association was found between whether the patients were aware they had received 
a genetic test and their perceived risk of being diagnosed with PC (Figure 3a, P = 0.68; Fisher’s 
exact test), or dying of PC (Figure 3b, P = 0.65), nor with their intention to have a repeat PSA test 
within 2 years (Figure 3c, P = 0.08). In contrast, a strong positive correlation was found between the 
patients’ actual measured genetic risk and their perceived risk of getting PC (Figure 3d, P = 2.6E-
20; Fisher’s exact test) and dying of PC (Figure 3e, P = 3.9E-9), as well as their intention for a repeat 
PSA test (Figure 3f, P = 2.2E-5). A possibility remains that this association was driven by the group of 
Table 2 Summary of patient characteristics (N = 555)
Characteristics n (%)a
Median age at inclusion, years (IQR) 63.4 (56.7 to 68.9)
Median PSA at inclusion (IQR) 1.1 (0.7 to 2.0)
PSA levels
<1 ng/ml 213 (38.4)
≥1 ng/ml 342 (61.6)
Unknown 0 (0.0)
Lifetime PC risk
Average risk 482 (86.8)
High risk 73 (13.2)
Unknown 0 (0)
General wellbeing (scale 1–5), mean (SD) 3.39 (0.79)
Reason to get PSA testb
Urinary problems 185 (33.3)
Saw the doctor for another health problem 140 (25.2)
As part of a regular health check 193 (34.8)
Worried about or ruling out having PC 351 (63.2)
Not intended before doctor recommendation 102 (18.4)
Family or friends or acquaintances advise 142 (25.6)
Friends or acquaintances living with or died from PC 245 (44.1)
Having another type of cancer 7 (1.3)
Previous elevated PSA level 8 (1.4)
Other reasons 60 (10.8)
aUnless stated otherwise. bParticipants able to select multiple reasons. IQR = interquartile range. PC = prostate 
cancer. PSA = prostate- specific antigen. SD = standard deviation.
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patients who were aware they had a genetic test; however, when the patients were stratified based 
on awareness, the correlation between the patients’ actual measured genetic risk and their perceived 
risks of getting PC and dying of PC remained significant regardless of awareness (P≤0.01 in all cases). 
In contrast, the intention to repeat the PSA test was only significantly associated with genetic risk in 
the subgroup of patients who were aware that they had had a genetic test (P = 5.3E-5).
In a study of the same cohort by a number of the present authors,23 a strong association between 
the genetic risk and whether a patient had a repeat PSA test was observed. Accordingly, 83.6% (61 
out of 73) of patients with a high genetic risk had a repeat PSA test within 2 years, while 20.5% (99 
out of 487) of patients with a normal risk had a repeat PSA test (Δ = 0.63; t- test, P<0.001; 95% CI = 
0.54 to 0.72).
Regression model for repeat PSA test
A multivariate Cox regression model revealed that a high genetic risk score was the most significant 
predictor of a repeated PSA test (hazard ratio (HR) = 5.99; 95% CI = 4.09 to 8.79, P<0.001, Table 3). 
In addition, the intention for a repeat PSA test was also a significant independent predictor for having 
a repeat PSA test (HR = 1.2; 95% CI = 1.05 to 1.37, P = 0.007, Table 3). Awareness of having the 
genetic test and PSA level at inclusion (HR = 1.16) were borderline significant predictors of a repeat 
PSA test (P<0.1) in multivariate analysis, whereas perceived risk of getting PC or dying from PC were 
non- significant (P≥0.1). For those who had a repeat PSA test, the median time to repeat PSA was 380 
days (IQR 338 to 505 days) after the genetic risk assessment.
Discussion
Summary
This study found that almost half of the participants were unaware they had a genetic assessment 
of their lifetime risk for PC. Of those who were aware, up to 25% did not correctly report their risk; 
however, the results showed that the actual genetic risk, and not an awareness of having the genetic 
test correlated with the patients’ perceived risk of PC, their intention to repeat their PSA test, and 
whether they then had a repeat PSA test. Together, this appears to indicate that patients followed the 
advice given by their GP (that is, to repeat the PSA test or not), despite not necessarily comprehending 
the test result. Alternatively, the GPs may not have found it essential to convey the details of the test 
result and simply gave patients the recommendations.
Figure 2 Self- reported outcome of tests for PC. In total, 555 patients (482 with a normal risk, 73 with a high risk) 
were asked if they had received a genetic test (A). Patients who were aware of the genetic test (262 normal risk and 
44 high risk) were next asked about the result of the test (B). Out of all questionnaire responders, patients reported 
if their PSA levels were normal, elevated, or they did not know (or did not answer) (C). Answers were separated into 
bins, based on PSA level at inclusion. Fisher’s exact test was used to test for difference in distribution. NS = not 
significant. PC = prostate cancer. PSA = prostate specific antigen. ***P<0.001.
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Strengths and limitations
To the best of the authors' knowledge, this is the 
first prospective study using a genetic risk test 
to promote targeted PSA screening of high- risk 
individuals in general practice, coupled with 
assessment of patient behaviour. A strength of 
this study is the availability of data from registries 
in addition to the questionnaires. This enhanced 
the validity of the data, especially because many 
patients were not aware of the genetic test result. 
Furthermore, using registries made it possible to 
collect data at different time points (the genetic 
test and data on any follow- up PSA test 2 years 
later).
Since the inception of this study, more PC- 
related SNPs have been identified,12–14 making 
risk assessment potentially more precise. 
However, as the endpoint in the present study 
was patient behaviour and not PC diagnosis, the 
accuracy of the risk assessment is not expected 
to influence the results presented here.
The risk of performance bias was low as 
the intervention comprised only paper- based 
information and clinical advice, and no education 
or training of GPs was required. However, this will 
often be the case when new tests are introduced 
in health services.
Comparison with existing 
literature
The low awareness of participant’s genetic test 
result is consistent with a previous study where 
patients had poor recall of risk figures given 
to them in genetic counselling sessions.30 This 
raises questions over whether patients actually 
understand the meaning and purpose of the test. 
A potential reason for this low awareness could 
be that the decision to test was not based on 
patients’ requests; the tests were offered by their 
GP. The authors speculate that patients might 
have taken the test simply because more testing 
is felt to be 'better'.22,31
The strong direct effect of lifetime risk for PC on 
follow- up PSA tests, despite the patients’ limited 
awareness of having the genetic test, suggests 
that GPs play an important role in the decision 
about follow- up PSA testing. While it is not 
known how (and whether) the GPs conveyed the 
purpose of the test and the result to the patients, 
patient behaviour and risk perception was 
changed following the genetic risk assessment 
process. This likely indicates that patients largely 
followed their GPs' recommendations. This is 
even more evident for patients who were not 
aware of their normal (that is, non- elevated) 
Figure 3 Self- reported perceived risk of getting a PC 
diagnosis, dying of PC, or intention of a repeat PSA 
test. Patients were asked about their perceived risk of 
getting PC and/or dying from PC on a scale of 1–5, 
as well as their intent to have a repeat PSA test within 
2 years on a scale of 1–4. The perceived risks and 
intention were plotted against awareness of having the 
genetic test (A- C), or the actual test result of measured 
genetic risk (D- F). Fisher’s exact test was used to test 
for difference in distribution. PC = prostate cancer. 
PSA = prostate specific antigen. NS = not significant. 
***P<0.001.
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genetic risk, but still had fewer PSA tests within 2 years.23 The relatively smaller indirect effect through 
perceived risk is consistent with earlier studies that found limited effects of long- term genetic testing 
on perceived risk.32
Implications for research and practice
The simplicity of the intervention, combined with the differences between patients with normal and high 
lifetime risk at follow- up PSA testing, makes this intervention a candidate for broader implementation 
to enhance appropriate PSA testing. However, before doing this, further research about the potential 
effects of this genetic test is required. First, the low awareness among patients receiving a genetic 
test provides a challenge for broader implementation of this test. It is possible that the GP did not 
use the wording 'genetic test' per se, but rather a lifetime risk test and, as such, it is not expected 
from the patients to know they had a genetic test. However, it is believed that the implications of the 
low awareness of a genetic test would have little impact on the decision- making process. Rather, a 
tangible recommendation is provided (that is, have an annual PSA test, or no benefit from screening). 
The effect of this recommendation can be seen in the data.
Further studies are required to determine how to communicate the test results effectively to 
patients, and to evaluate whether the genetic test could be integrated with a decision aid to support 
informed decision- making between men and their GP about appropriate PSA testing. Second, 
this report did not focus on the effect of the intervention on overall PSA test usage, as this has 
already been addressed elsewhere.23 Future studies should assess both the effects of communication 
strategies and offering a genetic test for lifetime PC risk on the number of PC diagnoses. Ideally, 
such future studies should include an optimised genetic test that includes all currently known PC risk 
variants.
Despite limited understanding of test results, offering a genetic test to assess the lifetime risk of PC 
altered the behaviour of patients about having a repeat PSA test within 2 years. Such an intervention 
could, in the future, form the basis for actively supporting informed decision- making between men 
and their GP in routine practice.
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Table 3 Cox regression analysis for repeat PSA test (N = 555, 160 with repeat PSA test). Uni- and multi- variate Cox regression, using 
genetic risk score, awareness of having a genetic test, PSA level at inclusion, perceived risk of PC, perceived risk of dying from PC, 
and intention for a repeat PSA were investigated as potential explanatory variables for actually having a repeat PSA test within 2 
years.
Univariate Multivariate
Variable Characteristics HR (95% CI) P value C- indexa HR (95% CI) P value
Genetic risk Normal versus high 8.11
(5.83 to 11.29)
<0.001 0.66 5.99
(4.09 to 8.79)
<0.001
Awareness of having 
a genetic test
No versus yes 1.23
(0.90 to 1.69)
0.193 0.53 1.32
(0.95 to 1.83)
0.099
PSA at inclusion Continuous 1.24
(1.05 to 1.46)
0.0097 0.56 1.16
(0.98 to 1.38)
0.083
Perceived risk for PC 1–5 2.13
(1.68 to 2.71)
<0.001 0.62 1.2
(0.83 to 1.74)
0.331
Perceived risk for 
dying of PC
1–5 1.77
(1.38 to 2.28)
<0.001 0.59 1.11
(0.79 to 1.57)
0.553
Intention for repeat 
PSA test
1–4 1.35
(1.18 to 1.54)
<0.001 0.62 1.2
(1.05 to 1.37)
0.007
aC- index, Harrell’s concordance index. HR = hazard ratio. PC = prostate cancer. PSA = prostate specific antigen.
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